Javier Gonzalez Cosme
Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1114449022
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 320 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations.
Across 320 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$764
- Xeris Pharmaceuticals, Inc.$726
- Novo Nordisk$653
- Novartis$615
- Lilly USA, LLC$455
- Bayer$432
- plus $4K from 28 others
What the payments were for
- Food & beverage$7,431100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 32 | $764 |
| Xeris Pharmaceuticals, Inc. | 33 | $726 |
| Novo Nordisk | 27 | $653 |
| Novartis | 34 | $615 |
| Lilly USA, LLC | 27 | $455 |
| Bayer | 15 | $432 |
| Insulet Corporation | 15 | $427 |
| Sanofi-aventis U.S. LLC | 14 | $408 |
| Dexcom, Inc. | 10 | $378 |
| Boehringer Ingelheim | 14 | $269 |
| AstraZeneca(2 entities) | 10 | $252 |
| Radius Health, Inc. | 10 | $248 |
| Tandem Diabetes Care, Inc. | 8 | $219 |
| AbbVie(2 entities) | 5 | $211 |
| Amneal Pharmaceuticals LLC | 11 | $189 |
| Mannkind Corporation | 7 | $158 |
| Sequel Med Tech, LLC | 6 | $137 |
| Cequr Corporation | 1 | $118 |
| Recordati_rare_diseases_inc. | 5 | $106 |
| BETA Bionics, Inc. | 6 | $100 |
| Pfizer | 4 | $74 |
| Ionis Pharmaceuticals, Inc. | 3 | $61 |
| Ascendis Pharma Endocrinology Inc | 3 | $55 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Amphastar Pharmaceuticals, Inc. | 2 | $49 |
| Amgen(2 entities) | 2 | $48 |
| Halozyme Inc | 2 | $41 |
| Antares Pharma, Inc. | 2 | $41 |
| Kyowa Kirin, Inc. | 2 | $34 |
| IBSA Pharma Inc. | 2 | $30 |
| Lifescan, Inc. | 2 | $30 |
| Rhythm Pharmaceuticals, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$247
- GVOKE HYPOPEN$126
- DEXCOM G7 GSS (161)$125
- Kerendia$122
- Ozempic$119
- CeQur Simplicity$118
- Omnipod$115
- SOLIQUA 100/33$112
How this compares
$7,431 in reported general payments places this provider in the 65th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Other endocrinology, diabetes & metabolism in Miami
- Jay SkylerMiami$2.2M
- Eugenio Angueira-SerranoMiami$603K
- Rodolfo GalindoMiami$229K
- Camillo RicordiMiami$128K
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.